Application of eculizumab, a terminal complement inhibitor, in the management of atypical hemolytic uremic syndrome in a 14-month-old Chinese pediatric patient: a case report

• المؤلفون الرئيسيون: Xin Wei (مؤلف), Xinzhu Liu (مؤلف), Yingying Yu (مؤلف), Wei Xie (مؤلف), Wentao Luo (مؤلف), Ye Tu (مؤلف), Shuhong Bu (مؤلف), Guimei Guo (مؤلف)
• التنسيق: كتاب
• منشور في: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Eculizumab, a recombined humanized monoclonal antibody which possesses high affinity for the complement protein C5, is a therapeutic agent utilized in the treatment of atypical hemolytic uremic syndrome (aHUS) by inhibiting the terminal complement complex C5b-9. In a pediatric patient with aHUS of 1...